US Patent Issued to Vivoryon Therapeutics on May 27 for "Crystalline pharmaceutically acceptable salt and polymorphic form of the glutaminyl cyclase inhibitor Varoglutamstat" (German Inventor)

ALEXANDRIA, Va., June 17 -- United States Patent no. 12,312,335, issued on May 27, was assigned to Vivoryon Therapeutics N.V. (Halle, Germany).

"Crystalline pharmaceutically acceptable salt and polymorphic form of the glutaminyl cyclase inhibitor Varoglutamstat" was invented by Ulrich Heiser (Halle, Germany).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention is concerned with a crystalline pharmaceutically acceptable salt of the glutaminyl cyclase inhibitor Varoglutamstat. Varoglutamstat is chemically designated as(S)-1-(1H-benzo[d]imidazol-5-yl)-5-(4-propoxyphenyl) imidazolidin-2-one and is also known under the code PQ912. The invention further relates to a polymorphic form of the hydrochlo...